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Objectives: The nutraceutical approach to the management of metabolic syndrome
(MetS) might be a promising strategy in the prevention of cardio-metabolic risk. Low-dose
bergamot-derived polyphenolic fraction (BPF) has been proven effective in patients with
MetS, as demonstrated by a concomitant improvement in lipemic and glycemic profiles.
The present study was aimed to further explore, in a sample of subjects receiving second
generation antipsychotics (SGAs), the effects on body weight and metabolic parameters
of a low dose of BPF (500 mg/day) administered for 60 days.
Methods: Twenty-eight outpatients treated with SGAs assumed BPF at single daily dose
of 500 mg/day for 60 days. Body weight, BMI, fasting levels of glucose, total cholesterol,
high density lipoprotein cholesterol, low density lipoprotein cholesterol and triglycerides
were determined; moreover, Brief Psychiatric Rating Scale (BPRS) was administered.
Results: Low-dose BPF administration did not change clinical and metabolic
parameters, as well as clinical symptoms in the study sample. At the end of the trial,
among completers (n = 24) only nine patients (37.5%) reached an LDL reduction >0 but
<50%.
Conclusions: Our results demonstrate that patients treated with SGAsmay need higher
BPF doses for obtaining the positive effects on body weight and metabolic parameters
previously found in the general population at lower doses.
Keywords: bergamot-derived polyphenolic fraction, metabolic syndrome, body weight, hyperlypemia,
hyperglycemia, second generation antipsychotics
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INTRODUCTION
Metabolic syndrome (MetS), a cluster of risk factors including
obesity, dyslipidemia, glucose intolerance, insulin resistance (or
hyperinsulinemia) and hypertension, is highly predictive of type
2 diabetes and cardiovascular disease (Grundy et al., 2004).
People with psychiatric disorders usually show a high
incidence of MetS, and especially schizophrenia subjects exhibit
prevalence rates much higher than general population and
healthy controls (Casey, 2005). Although schizophrenia appears
to be able to represent itself a risk factor for MetS, such risk is
further exacerbated by the use of atypical antipsychotic agents
(Haddad, 2004; Coccurello et al., 2009; Coccurello and Moles,
2010a,b; Miron et al., 2014). Moreover, atypical antipsychotics
polytherapy, compared to monotherapy, may be independently
associated with an increased risk of pre-MetS and with high rates
of MetS (Reynolds and Kirk, 2010; Misawa et al., 2011).
Despite the availability of multiple pharmacological
interventions for the treatment of MetS-related alterations,
these therapeutic strategies often present several side effects,
such as myalgia, myopathy, liver disease and rhabdomyolysis
and, furthermore, an inadequate control of cardiovascular
disease (Alsheikh-Ali and Karas, 2009; Joy and Hegele, 2009),
thus suggesting the need to find new potential therapies.
The nutraceutical approach to themanagement ofMetSmight
be a promising strategy in the prevention of cardio-metabolic
risks. In particular, the polyphenols used in clinical practice
have demonstrated to be effective in the treatment of diabetes
mellitus,MetS and their complications and to be able to positively
modulate multiple biochemical and clinical end-points (Davì
et al., 2010).
Bergamot (Citrus bergamia) is an endemic plant of the
Southern Italy, which differs from other citrus fruits for
flavonoids and flavonoid glycosides composition (neoeriocitrin,
neohesperidin, naringin, rutin, poncirin, roifolin, and
neodesmin), and for their high amount (Nogata et al., 2006;
Misawa et al., 2011). As well as to a non-specific antioxidant
action, lipid-lowering and glucose-lowering actions of BPF may
be attributed to several specific mechanisms (Fraga et al., 2010).
In particular, the hypolipidemic effect is related to the selective
inhibition of the hydroxymethylglutaryl CoA reductase and to
the reduction of the activity of phosphatidate phosphohydrolase
enzymes, whereas the hypoglycemic action is associated with the
increase of the activities of AMP kinase, sirtuin-1 and, in muscle
cells and liver, glucose transporter GLUT-4 (Ciccone et al., 2015).
Recently, the therapeutic potential of bergamot derivatives
has been investigated in human studies: it was shown that
bergamot-derived polyphenolic fraction (BPF) has beneficial
effects in patients with MetS, as demonstrated by a concomitant
improvement in lipemic and glycemic profiles, and by the
improvement of altered endothelium-mediated vasodilation
(Mollace et al., 2011; Gliozzi et al., 2014; Toth et al., 2016).
Specifically,Mollace et al. (2011) have demonstrated that BPFwas
effective already after the administration of 500 mg/day for 30
days, and that differences between 500 and 1,000mg dosages were
statistically significant only for high density lipoprotein (HDL)
cholesterol. More recently, we tested the efficacy of BPF at the
daily dose of 1,000mg administered for 30 days in a sample
of 15 outpatients treated with second generation antipsychotics
(SGAs); our findings were encouraging, since BPF administration
resulted in a statistically significant reduction of body weight (P
= 0.004) and in a trend for body mass index (BMI) decrease
(P = 0.005); however, no effects on metabolic parameters were
observed (Bruno et al., 2016).
Based on the evidence from the literature, including our
previous clinical results, the present study was aimed to further
explore, in a sample of subjects receiving SGAs, the effects on
body weight and metabolic parameters of a low dose of BPF (500
mg/day) administered for 60 days.
MATERIALS AND METHODS
Study Design
This was a 60-day, open-label, preliminary study aimed to
evaluate the efficacy and safety of adjunctive BPF to atypical
antipsychotics therapy. BPF (Bergamot Polyphenolic Fraction
BPF R©, H&AD S.r.l—Bianco (RC), Italy) was administered in
capsules at the oral daily dose of 500 mg/day and was maintained
unchanged until the end of the trial at day 60. The concentration
of 5 main flavonoids per capsule was: neoheriocitrin (55,535
mg), naringin (58,903 mg), neohesperidin (62,966 mg), melitidin
(7,958 mg) and brutieridin (24,371 mg); excipients of any type
were not present. During the study, no additional medications,
including aspirin or non-steroidal anti-inflammatory drugs, were
allowed. The study was carried out at the Psychiatry Unit of
the University Hospital of Messina, Italy. The protocol has been
approved by the Ethics Committee of the University of Messina,
Italy.
Subjects
Twenty-eight outpatients, 15 men and 13 women, aged 21–65
years, in treatment with SGAs (clozapine, olanzapine, quetiapine,
risperidone and paliperidone), were included in this study. All
patients had been on monotherapy for at least 3 months; the
dose had been stable for at least 1 month before the study
and was left unchanged throughout the study. The patients did
not receive any antidepressant or anticonvulsant drugs for a
period of 2 months before the study. Furthermore at enrollment,
all subjects received standardized dietary advice in order to
reduce the variability of their baseline metabolic values. Patients
with any significant concurrent medical illnesses, organic brain
disorder, mental retardation, pregnant or lactating women, or
a current diagnosis of alcohol/drug dependence were excluded.
All the patients provided written informed consent after a full
explanation of the protocol design, and the study was conducted
according to the Declaration of Helsinki.
Assessment
Patients attended three visits: initial screening (week −1),
inclusion (day 0), and final visit (day 60).
A physical examination was performed to measure vital signs
[blood pressure, heart rate, body weight (BW) and body mass
index (BMI)].
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Standard laboratory methods were used to determine fasting
levels of glucose, total cholesterol, HDL, and triglycerides. Low
density lipoprotein (LDL) cholesterol was determined by the
Friedewald et al. calculation (LDL = total cholesterol – (HDL +
[triglycerides/5]) (Friedewald et al., 1972).
The Brief Psychiatric Rating Scale (BPRS) (Overall and
Gorham, 1962) was administered by two senior psychiatrists with
at least 5 years of clinical experience and trained on rating scales;
each patient had the same person conducting clinical interviews
and administering psychometric and neuropsychological tests.
All physical information, laboratory measurements and data
for clinical and neuropsychological assessments were obtained
at baseline and at the end of the study (approximately 60 days
apart).
Adverse effects, either observed or spontaneously reported,
were recorded at each visit and classified in terms of onset,
duration, severity, action taken, and outcome. In order to
monitor the adherence to the study protocol, weekly telephone
calls during the study period and a pill count on the last day (day
60) were carried out.
Measurement of Serum Concentrations of
Antipsychotics
Steady-state serum concentrations of clozapine, olanzapine,
risperidone, 9-hydroxyrisperidone (or paliperidone) and
quetiapine were measured by HPLC at day 0 and day 60
(Avenoso et al., 1998, 2000; D’Arrigo et al., 2006; Santoro et al.,
2008).
Statistical Analysis
Before the start of the study, sample size was calculated: under
the assumption of a significant level of 0.05 with a power of 0.80
and an effect size of 0.50, a minimal sample size of 28 subjects
was determined. Due to the small sample size, the analyses
were carried out by non-parametric tests. An intention-to-treat
analysis (ITT) with last-observation-carried forward (LOCF) was
performed. Continuous data were expressed as mean ± SD and
the within group differences in efficacy ratings between baseline
and final test were analyzed by the Wilcoxon rank sum test.
To measure the magnitude of a treatment effect, effect size was
provided by using Cohen’s d statistic and was considered small
when lower than 0.50, moderate when ranging from 0.50 to 0.79,
and large when equal to or greater than 0.80. The statistical
analysis was performed with SPSS 16.0 software (SPSS Inc.,
Chicago, Ill).
RESULTS
Baseline characteristics, duration of SGAs prior treatment, SGAs
type and daily dose in enrolled/completers subjects are detailed
in Table 1. Twenty-four patients completed the study (85.7%
completion rate); there were four premature dropouts, due to
non-compliance with the visits.
Treatment Response
Table 2 shows the baseline and final values of the different
vital signs (blood pressure, heart rate, BW and BMI) and
TABLE 1 | Demographic and clinical characteristics of the subjects
enrolled.
Patients entered/completers 28/24
Sex (M/F) 15/13
Age (years), mean ± SD 45.8 ± 11.7
Educational level (years), mean ± SD 9.6 ± 3.1
Duration of prior AP treatment (months), mean ± SD 25.6 ± 34.1
SGAs (Dose range – mg/d) n. entered/completers
Olanzapine (5–20 mg/d) 7/7
Clozapine (100–350 mg/d) 7/6
Quetiapine (50–100 mg/d) 6/5
Risperidone (3–4 mg/d) 4/3
Paliperidone (9–12 mg/d) 4/3
metabolic parameters (triglycerides, total cholesterol, HDL, LDL,
and glucose), and the effect size for the sample group: at day
60, within-group comparison revealed that BPF administration
did not change the values of the considered parameters.
Effect sizes were small in each explored clinical and metabolic
parameters.
Response Rate
LDL reduction was chosen for treatment efficacy evaluation
because it is the most commonly used surrogate endpoint for
cardiovascular disease reduction, and it is the primary target
for statin therapy in cholesterol-lowering guidelines (Perk et al.,
2012). Treatment response was defined as a reduction in LDL >0
but <50% or ≥50%, according to the current statin guidelines
(Perk et al., 2012; Stone et al., 2014).
Among completers (n = 24), 9 individuals (37.5%)
experienced an LDL reduction >0 but <50%, whereas 15
subjects (63.5%) experienced no reduction or an increase in LDL
compared with baseline. None of the patients experienced an
LDL reduction ≥50%.
Adverse Effects
BPF adjunctive treatment was well tolerated at 500 mg/day
dosage: no adverse effects were recorded in our sample during
the 60-days treatment period. Moreover, regarding clinical
symptoms, no significant changes emerged at the end of the study
in the BPRS scores (Table 3), suggesting that psychopathological
symptoms did not worsen during the trial. Finally, no acute
extrapyramidal effects, seizures, or cardiac events occurred.
Serum Concentrations of Antipsychotics
Serum concentrations of clozapine, olanzapine, risperidone, 9-
hydroxyrisperidone (or paliperidone) and quetiapine were not
affected significantly by administration of BPF. Concerning the
two antipsychotics more frequently administered to patients
participating to the study, namely olanzapine (7 patients) and
clozapine (6 patients), mean steady-state serum concentrations
of olanzapine were 29.1 ± 12.4 ng/mL at day 0 and 25.0 ± 9.7
ng/mL at day 60, while serum concentrations of clozapine were
551± 139 ng/mL at day 0 and 572± 124 ng/mL at day 60.
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TABLE 2 | Clinical and metabolic changes, and effect sizes for efficacy measures in patients receiving BPF at baseline and day 60 (LOCF).
Baseline (T0) Day 60 (T1) Wilcoxon test T0 vs. T1 Cohen’s d
Mean SD Mean SD Z P
Systolic blood pressure (mm HG) 122.20 17.26 124.96 14.96 −1.053 0.292 0.2
Diastolic blood pressure (mm HG) 75.88 9.40 77.56 9.04 −0.888 0.375 0.2
Heart rate (b/m) 80.92 12.93 82.92 16.46 −0.713 0.476 0.1
Body weight (kg) 84.07 23.18 84.20 23.54 −0.190 0.849 0
Body mass index (kg/m2) 30.50 7.55 30.52 7.57 −0.047 0.962 0
Triglycerides (mg/dl) 109.32 51.94 120.56 64.76 −1.141 0.254 0.2
Total cholesterol (mg/dl) 202.56 32.97 205.84 23.80 −1.330 0.184 0.1
HDL (mg/dl) 55.92 19.58 56.21 17.20 −0.244 0.807 0
LDL (mg/dl) 124.77 26.85 125.52 20.13 −0.357 0.721 0
Glucose (mg/dl) 93.56 17.4 95.76 20.82 −1.596 0.111 0.1
LOCF indicates last observation carried forward.
TABLE 3 | Psychopathological changes, and effect sizes for efficacy measures in patients receiving BPF at baseline and day 60 (LOCF).
Baseline (T0) Day 60 (T1) Wilcoxon test T0 vs. T1 Cohen’s d
Mean SD Mean SD Z p
BPRS
Anxiety-depression 8.80 3.66 8.88 3.48 0.000 1.000 0
Anergia 7.76 3.52 7.56 3.48 −0.603 0.546 0
Thinking disorder 6.12 2.22 5.72 2.52 −1.411 0.158 0.2
Activity 5.56 1.89 5.52 1.91 −0.104 0.917 0
Hostility-suspicion 4.92 2.73 4.68 2.19 −0.256 0.798 0.1
Total score 33.16 7.90 32.36 8.95 −0.706 0.480 0.1
LOCF indicates last observation carried forward.
DISCUSSION
The metabolic effects of atypical antipsychotics represent
a serious medical problem to be addressed with different
therapeutic approaches in order to improve the life expectancy
of subjects with mental disorders. Cross-sectional studies have
reported MetS prevalence rates of 11–69% in pharmacologically
treated psychiatric patients, and of 4–26% in drug-naïve patients;
longitudinal studies have showed baseline prevalence rates
between 0 and 14% in drug-naïve patients, increased up to a
maximum of 52% after 3 months of antipsychotics treatment
(Malhotra et al., 2013). Among SGAs, clozapine, olanzapine, and
quetiapine are particularly associated with weight gain, as well
as with adiposity-dependent and possibly adiposity-independent
glucose dysregulation and dyslipidemia (Newcomer, 2007).
In a previous study, we found that a moderate BPF dose
(1,000 mg) for 30 days significantly reduced body weight in
SGAs-treated patients, suggesting that BPF could be an effective
and safe agent to prevent weight gain associated with atypical
antipsychotic use (Bruno et al., 2016). On the basis of such
encouraging results, we had the aim to verify the potential use
of low-dose BPF administered for a longer period.
Our findings indicated that adjunctive BPF treatment at the
oral dose of 500 mg/day administered for 60 days appeared
to be scarcely effective for reducing vital signs and metabolic
parameters in the study sample. At the end of the trial only nine
patients (37.5%) reached a minimal LDL reduction according
to the current statin guidelines (Perk et al., 2012; Stone et al.,
2014), whereas no patients experienced an LDL reduction
≥50%.
BPF adjunctive treatment was well tolerated at 500 mg/day
dosage, as shown by the lack of pharmacokinetic effects on
hematic concentrations of antipsychotics, and by the dropout
causes, all unrelated to adverse and/or unwanted events,
confirming previous studies on safety profile of bergamot extract
(Mollace et al., 2011; Gliozzi et al., 2014; Toth et al., 2016).
Moreover, regarding psychopathological symptoms, BPF add-
on treatment did not modified the explored domains, since no
significant changes in BPRS scores were observed.
Our previous results (Bruno et al., 2016) showing
a significant reduction of body weight with BPF (1,000
mg/day) supplementation were not confirmed at lower doses;
furthermore, our findings did not confirm the beneficial effect
of low-dose BPF on lipid and glycemic profiles previously found
in the literature (Mollace et al., 2011). In the attempt to explain
such results, it should be borne in mind that the pharmacological
mechanisms underlying the association of antipsychotics with
metabolic disorders (Taylor and McAskill, 2000; Matsui-Sakata
et al., 2005) may be different from the mechanisms responsible
for MetS in patients who do not take this class of drugs.
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The findings of the present study need to be carefully
interpreted because of the presence of several limitations, such as
the small sample size, the open design, and the lack of a control
group. Additionally, all participants in this study belonged to
a restricted area of Southern Italy; due to differences in genes,
lifestyles and diets (e.g., Mediterranean diet) among ethnic
groups, it seems difficult to generalize these results to other
populations.
Our current and earlier results tend to suggest that patients
treated with SGAs may need higher BPF doses (>1,000 mg)
for obtaining the positive effects on body weight and metabolic
parameters previously found in the general population at lower
doses.
Further clinical trials with adequately-powered and well-
designed methodology are needed to better evaluate the
effectiveness of the BFP on SGA-induced metabolic side
effects, and to identify potential nutraceutical strategies for the
prevention of MetS in subjects with mental disorders.
AUTHOR CONTRIBUTIONS
AB, RZ, and MM designed the study, wrote the protocol, and
supervised the Method procedures, the various drafts and the
final version of themanuscript. GP and ESmanaged the literature
searches and wrote the first drafts of the manuscript. MCr, MCa,
and VS organized recruitment and collected data, contributed to
the literature search and writing of the manuscript. All Authors
contributed to and have approved the final manuscript.
ACKNOWLEDGMENTS
The authors thank all the participants and the whole staff of
the Section of Psychiatry, Department of Biomedical and Dental
Sciences and Morphofunctional Imaging, University of Messina,
Italy, for assistance with recruitment and data collection. We
thank Dr. Francesco Chirico, Agrumaria Reggina SRL, Reggio
Calabria, Italy, for technical support.
REFERENCES
Alsheikh-Ali, A. A., and Karas, R. H. (2009). The relationship of statins to
rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials.
Curr. Atheroscler. Rep. 11, 100–104. doi: 10.1007/s11883-009-0016-8
Avenoso, A., Facciolà, G., Campo, G. M., Fazio, A., and Spina, E. (1998).
Determination of clozapine, N-desmethylclozapine, and clozapine N-oxide
in human plasma by reverse phase high-performance liquid chromatography
with ultraviolet detection. J. Chromatogr. B,. Biomed. Appl. 714, 299–308.
doi: 10.1016/S0378-4347(98)00202-3
Avenoso, A., Facciolà, G., Salemi, M., and Spina, E. (2000). Determination
of risperidone and its major metabolite 9-hydroxy-risperidone in
human plasma by reversed phase liquid chromatography with
ultraviolet detection. J. Chromatogr. B. Biomed. Appl. 746, 173–181.
doi: 10.1016/S0378-4347(00)00323-6
Bruno, A., Pandolfo, G., Crucitti, M., Maisano, A., Zoccali, R. A., and Muscatello,
M. R. (2016). Metabolic outcomes of bergamot polyphenolic fraction
administration in patients treated with second-generation antipsychotics: a
pilot study. J. Nutr. Biochem. 40, 32–35. doi: 10.1016/j.jnutbio.2016.10.008
Casey, D. E. (2005). Metabolic issues and cardiovascular disease in
patients with psychiatric disorders. Am. J. Med. 118, 15S–22S.
doi: 10.1016/j.amjmed.2005.01.046
Ciccone, M. M., Zito, A., Cortese, F., Cecere, A., Moncelli, M., Gesualdo,
M., et al. (2015). Bergamot polyphenols: a phytotherapeutic approach to
hyperlipidemia and hypercholesterolemia. Control Pharmacol. 6, 120–124.
doi: 10.5567/pharmacologia.2015.120.124
Coccurello, R., Brina, D., Caprioli, A., Conti, R., Ghirardi, O., Schepis, F.,
et al. (2009). 30 days of continuous olanzapine infusion determines energy
imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.
J. Clin. Psychopharmacol. 29, 576-583. doi: 10.1097/jcp.0b013e3181bfe13e
Coccurello, R., and Moles, A. (2010a). Potential mechanisms of atypical
antipsychotic-induced metabolic derangement: clues for understanding
obesity and novel drug design. Pharmacol. Ther. 127, 210–251.
doi: 10.1016/j.pharmthera.2010.04.008
Coccurello, R., and Moles, A. (2010b). A murine model of atypical antipsychotic-
induced weight gain and metabolic dysregulation. Curr. Protoc. Neurosci. 52,
9.33. doi: 10.1002/0471142301.ns0933s52
D’Arrigo, C., Migliardi, G., Santoro, V., and Spina, E. (2006). Determination
of olanzapine in human plasma by reversed-phase high-performance liquid
chromatography with ultraviolet detection. Ther. Drug Monit. 28, 388–393.
doi: 10.1097/01.ftd.0000211800.66569.c9
Davì, G., Santilli, F., and Patrono, C. (2010). Nutraceuticals in
diabetes and metabolic syndrome. Cardiovasc. Ther. 28, 216–226.
doi: 10.1111/j.1755-5922.2010.00179.x
Fraga, C. G., Galleano, M., Verstraeten, S. V., and Oteiza, P. I. (2010). Basic
biochemical mechanisms behind the health benefits of polyphenols. Mol.
Aspects Med. 31, 435–445. doi: 10.1016/j.mam.2010.09.006
Friedewald, W. T., Levy, R. I., and Fredrickson, D. S. (1972). Estimation of the
concentration of low-density lipoprotein cholesterol in plasma, without use of
the preparative ultracentrifuge. Clin. Chem. 18, 499–502.
Gliozzi, M., Carresi, C., Musolino, V., Palma, E., Muscoli, C., Vitale, C., et al.
(2014). The effect of bergamot-derived polyphenolic fraction on LDL small
dense particles and non alcoholic fatty liver disease in patients with MS. Adv.
Biol. Chem. 4, 129–137. doi: 10.4236/abc.2014.42017
Grundy, S. M., Brewer, H. B. Jr., Cleeman, J. I., Smith, S. C. Jr., and
National Heart, Lung, and Blood Institute; American Heart Association
(2004). Definition of metabolic syndrome: report of the National Heart,
Lung, and Blood Institute/American Heart Association conference
on scientific issues related to definition. Circulation 109, 433–438.
doi: 10.1161/01.CIR.0000111245.75752.C6
Haddad, P. M. (2004). Antipsychotics and diabetes: review of non-prospective
data. Br. J. Psychiatry Suppl. 47, S80–S86. doi: 10.1192/bjp.184.47.s80
Joy, T. R., and Hegele, R. A. (2009). Narrative review:
statin-related myopathy. Ann. Intern. Med. 150, 858–868.
doi: 10.7326/0003-4819-150-12-200906160-00009
Malhotra, N., Grover, S., Chakrabarti, S., and Kulhara, P. (2013). Metabolic
syndrome in schizophrenia. Indian J. Psychol. Med. 35, 227–240.
doi: 10.4103/0253-7176.119471
Matsui-Sakata, A., Ohtani, H., and Sawada, Y. (2005). Receptor occupancy-based
analysis of the contributions of various receptors to antipsychotics-induced
weight gain and diabetes mellitus. Drug Metab. Pharmacokinet. 20, 368–378.
doi: 10.2133/dmpk.20.368
Miron, I. C., Baroanaˇ, V. C., Popescu, F., and Ionicaˇ, F. (2014). Pharmacological
mechanisms underlying the association of antipsychotics with metabolic
disorders. Curr. Health Sci. J. 40, 12–17. doi: 10.12865/CHSJ.40.01.02
Misawa, F., Shimizu, K., Fujii, Y., Miyata, R., Koshiishi, F., Kobayashi, M., et al.
(2011). Is antipsychotic polypharmacy associated with metabolic syndrome
even after adjustment for lifestyle effects? A cross-sectional study. BMC
Psychiatry 11:118. doi: 10.1186/1471-244X-11-118
Mollace, V., Sacco, I., Janda, E., Malara, C., Ventrice, D., Colica, C.,
et al. (2011). Hypolipemic and hypoglycaemic activity of bergamot
polyphenols: from animal models to human studies. Fitoterapia 82, 309–316.
doi: 10.1016/j.fitote.2010.10.014
Newcomer, J. W. (2007). Antipsychotic medications: metabolic and cardiovascular
risk. J. Clin. Psychiatry 68, 8–13.
Nogata, Y., Sakamoto, K., Shiratsuchi, H., Ishii, T., Yano, M., and Ohta, H. (2006).
Flavonoid composition of fruit tissues of citrus species. Biosci. Biotechnol.
Biochem. 70, 178–192. doi: 10.1271/bbb.70.178
Frontiers in Pharmacology | www.frontiersin.org 5 April 2017 | Volume 8 | Article 197
Bruno et al. Low-Dose BPF in SGAs-Treated Patients
Overall, J. E., and Gorham, D. R. (1962). The brief psychiatric rating scale. Psychol.
Rep. 10, 799–812. doi: 10.2466/pr0.1962.10.3.799
Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., et al.
(2012). European Guidelines on cardiovascular disease prevention in clinical
practice (version 2012). The Fifth Joint Task Force of the European Society
of Cardiology and Other Societies on Cardiovascular Disease Prevention in
Clinical Practice (constituted by representatives of nine societies and by invited
experts). Eur. Heart J. 33, 1635–1701. doi: 10.1093/eurheartj/ehs092
Reynolds, G. P., and Kirk, S. L. (2010). Metabolic side effects of antipsychotic drug
treatment—pharmacological mechanisms. Pharmacol. Ther. 125, 169–179.
doi: 10.1016/j.pharmthera.2009.10.010
Santoro, V., D’Arrigo, C., Migliardi, G., Muscatello, M. R., Micò, U., Cambria,
R., et al. (2008). Therapeutic drug monitoring of quetiapine: effect of
coadministration with antiepileptic drugs in patients with psychiatric disorders.
Open Clin. Chem. J. 1, 17–21. doi: 10.2174/1874241600801010017
Stone, N. J., Robinson, J., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C.
B., Eckel, R. H., et al. (2014). 2013 ACC/AHA guideline on the treatment
of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:
a report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 63, 2889–2934.
doi: 10.1016/j.jacc.2013.11.002
Taylor, D. M., and McAskill, R. (2000). Atypical antipsychotics and
weight gain–a systematic review. Acta Psychiatr. Scand. 101, 416–432.
doi: 10.1034/j.1600-0447.2000.101006416.x
Toth, P. P., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Biancucci,
T., et al. (2016). Bergamot reduces plasma lipids, atherogenic small
dense LDL, and subclinical atherosclerosis in subjects with moderate
hypercholesterolemia: a 6 months prospective study. Front. Pharmacol. 6:299.
doi: 10.3389/fphar.2015.00299
Conflict of Interest Statement: ES has previously received honoraria for speaking
and consultation from AstraZeneca, Boheringer-Ingelheim, Eli Lilly, Janssen,
Lundbeck, and Pfizer. The remaining authors declare no conflict of interest.
Copyright © 2017 Bruno, Pandolfo, Crucitti, Cacciola, Santoro, Spina,
Zoccali and Muscatello. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 6 April 2017 | Volume 8 | Article 197
